Literature DB >> 19235922

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.

Edoardo Missiaglia1, Joanna Selfe, Mohamed Hamdi, Daniel Williamson, Gerben Schaaf, Cheng Fang, Jan Koster, Brenda Summersgill, Boo Messahel, Rogier Versteeg, Kathy Pritchard-Jones, Marcel Kool, Janet Shipley.   

Abstract

Rhabdomyosarcomas (RMS) are the most common pediatric soft tissue sarcomas. They resemble developing skeletal muscle and are histologically divided into two main subtypes; alveolar and embryonal RMS. Characteristic genomic aberrations, including the PAX3- and PAX7-FOXO1 fusion genes in alveolar cases, have led to increased understanding of their molecular biology. Here, we determined the effect of genomic copy number on gene expression levels through array comparative genomic hybridization (CGH) analysis of 13 RMS cell lines, confirmed by multiplex ligation-dependent probe amplification copy number analyses, combined with their corresponding expression profiles. Genes altered at the transcriptional level by genomic imbalances were identified and the effect on expression was proportional to the level of genomic imbalance. Extrapolating to a public expression profiling dataset for 132 primary RMS identified features common to the cell lines and primary samples and associations with subtypes and fusion gene status. Genes identified such as CDK4 and MYCN are known to be amplified, overexpressed, and involved in RMS tumorigenesis. Of the many genes identified, those with likely functional relevance included CENPF, DTL, MYC, EYA2, and FGFR1. Copy number and expression of FGFR1 was validated in additional primary material and found amplified in 6 out of 196 cases and overexpressed relative to skeletal muscle and myoblasts, with significantly higher expression levels in the embryonal compared with alveolar subtypes. This illustrates the ability to identify genes of potential significance in tumor development through combining genomic and transcriptomic profiles from representative cell lines with publicly available expression profiling data from primary tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235922     DOI: 10.1002/gcc.20655

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  42 in total

1.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

2.  FGFR1 expression and gene copy numbers in human lung cancer.

Authors:  Lukas H Kohler; Masoud Mireskandari; Thomas Knösel; Annelore Altendorf-Hofmann; Almut Kunze; Andreas Schmidt; Norbert Presselt; Yuan Chen; Iver Petersen
Journal:  Virchows Arch       Date:  2012-05-31       Impact factor: 4.064

Review 3.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

4.  The unique expression and function of miR-424 in human placental trophoblasts.

Authors:  Jean-Francois Mouillet; Rogier B Donker; Takuya Mishima; Tina Cronqvist; Tianjiao Chu; Yoel Sadovsky
Journal:  Biol Reprod       Date:  2013-08-01       Impact factor: 4.285

5.  Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Authors:  Luigi Formisano; Kimberly M Stauffer; Christian D Young; Neil E Bhola; Angel L Guerrero-Zotano; Valerie M Jansen; Mónica M Estrada; Katherine E Hutchinson; Jennifer M Giltnane; Luis J Schwarz; Yao Lu; Justin M Balko; Olivier Deas; Stefano Cairo; Jean-Gabriel Judde; Ingrid A Mayer; Melinda Sanders; Teresa C Dugger; Roberto Bianco; Thomas Stricker; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

6.  Multiple sites of highly amplified DNA sequences detected by molecular cytogenetic analysis in HS-RMS-2, a new pleomorphic rhabdomyosarcoma cell line.

Authors:  Eiji Takaoka; Hiroshi Sonobe; Kunihiro Akimaru; Shuji Sakamoto; Taro Shuin; Masanori Daibata; Takahiro Taguchi; Akira Tominaga
Journal:  Am J Cancer Res       Date:  2012-02-19       Impact factor: 6.166

7.  miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer.

Authors:  Dacheng Wen; Songhe Li; Fujian Ji; Hong Cao; Weidong Jiang; Jiaming Zhu; Xuedong Fang
Journal:  Tumour Biol       Date:  2013-01-09

8.  A new bright-field dual-colour chromogenic and silver in situ hybridization method for the detection of FGFR1 gene copy number status.

Authors:  Diana Boehm; Wenzel Vogel; Alina Franzen; Andreas Schrock; Friedrich Bootz; Lynn E Heaseley; Martin Braun; Sven Perner
Journal:  Virchows Arch       Date:  2014-03-02       Impact factor: 4.064

9.  Chromosomal and genetic imbalances in Chinese patients with rhabdomyosarcoma detected by high-resolution array comparative genomic hybridization.

Authors:  Chunxia Liu; Dongliang Li; Jianming Hu; Jinfang Jiang; Wei Zhang; Yunzhao Chen; Xiaobin Cui; Yan Qi; Hong Zou; Wenjie Zhang; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

Review 10.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.